Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc. (Nasdaq: NBIX) is a premier neuroscience-focused biopharmaceutical company based in San Diego. Established in 1992, the company is committed to developing and commercializing innovative pharmaceutical products that address unmet medical needs. Neurocrine Biosciences specializes in treatments for neurological, neuroendocrine, and neuropsychiatric disorders, impacting some of the largest pharmaceutical markets worldwide, including segments dealing with endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other related conditions.
The company’s extensive portfolio includes FDA-approved treatments such as INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, along with investigational candidates like elagolix, opicapone, and crinecerfont. Notable late-stage clinical programs are:
- Elagolix: A hormone-releasing antagonist for women's health, particularly in treating endometriosis and uterine fibroids in collaboration with AbbVie.
- Opicapone: A catechol-O-methyltransferase (COMT) inhibitor for Parkinson's disease patients.
- Ingrezza: For treating Tourette syndrome and other movement disorders.
Recently, Neurocrine announced the initiation of a Phase 1 clinical study for NBI-1076986, an investigational M4 subtype-selective muscarinic acetylcholine receptor antagonist aimed at treating movement disorders such as Parkinson's disease tremor and dystonia. This is part of their broader muscarinic receptor-focused portfolio, which includes a variety of small molecule M1, M1/M4, and M4 agonists acquired from Nxera Pharma.
Neurocrine's robust pipeline also includes the CAHtalyst™ studies, which focus on crinecerfont for congenital adrenal hyperplasia (CAH), demonstrating significant potential in reducing glucocorticoid doses while maintaining androgen control. Their recent presentations at the American Association of Clinical Endocrinology 2024 Annual Meeting and the European Congress of Endocrinology 2024 highlight their continuous advancements.
Financially, Neurocrine Biosciences maintains a strong position with a multi-billion-dollar product in INGREZZA, and a diverse pipeline of 17 clinical development programs. Notably, the company announced the retirement of CEO Kevin Gorman, Ph.D., with Kyle Gano, Ph.D., set to succeed him in October 2024, ensuring a seamless transition and continued focus on innovative treatments.
For more comprehensive insights and updates, visit Neurocrine Biosciences and follow them on LinkedIn, X (formerly Twitter), and Facebook.
Neurocrine Biosciences (NASDAQ: NBIX) presents data at SLEEP 2022 regarding sleep disturbances in Parkinson's disease (PD), highlighting the impact of OFF episodes on sleep quality. The analysis reveals that 34.4% of participants experienced OFF episodes before sleep, lasting a mean of 1.8 hours. Among those waking at night, 81% were OFF for an average of 1 hour. The findings underscore the need for better understanding and management of sleep issues in PD patients. ONGENTYS, an adjunct therapy to levodopa, aims to improve treatment outcomes for these patients.
Neurocrine Biosciences (Nasdaq: NBIX) announced the repurchase of approximately $179.4 million of its existing 2.25% Convertible Senior Notes due in 2024 for an estimated $224.0 million. This move aims to reduce convertible debt by around 60% over two years, decreasing outstanding notes to about $201.8 million. The repurchases, expected to close by June 14, 2022, may influence the stock's market price. CFO Matt Abernethy emphasized the focus on minimizing dilution for shareholders and advancing clinical programs.
Neurocrine Biosciences (Nasdaq: NBIX) recently announced the presentation of new data on INGREZZA (valbenazine) at the American Psychiatric Association (APA) Annual Meeting from May 21-25, 2022. The post hoc analysis of two long-term studies showed significant improvements in tardive dyskinesia (TD) symptoms after 48 weeks of treatment, maintaining psychiatric stability. Additional presentations at the conference will cover related topics including telehealth services and a patient-centric study on TD treatment.
On May 12, 2022, Neurocrine Biosciences announced that the FDA granted Orphan Drug Designation for valbenazine to treat chorea associated with Huntington disease (HD). This follows the Phase 3 KINECT-HD study results, which evaluated valbenazine's efficacy and safety in adults with HD. The company's CEO emphasized its commitment to developing treatments for rare diseases. Currently, the KINECT-HD2 open-label study is ongoing to assess long-term safety of valbenazine. The supplemental new drug application (sNDA) is anticipated later this year, aiming to provide new options for HD patients.
Neurocrine Biosciences (NBIX) reported Q1 2022 net product sales of $303 million for INGREZZA, marking a 32% increase year-over-year. Total revenues reached $310.6 million, up from $236.6 million a year earlier. The company reiterated its full-year sales guidance for INGREZZA between $1.25 - $1.35 billion, anticipating 20% growth. GAAP net income was $13.9 million, down from $32.1 million in Q1 2021. Increased R&D and SG&A expenses were noted, correlating with expanded clinical programs and salesforce efforts.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 11:20 a.m. PT in Las Vegas. CEO Kevin Gorman and CFO Matt Abernethy will represent the company. The presentation will be available via live webcast on the company's website, with a replay accessible after one hour post-event for about a month. Neurocrine focuses on developing treatments for neurological and neuropsychiatric disorders, with a range of FDA-approved therapies and ongoing clinical programs.
Neurocrine Biosciences (Nasdaq: NBIX) announced its first quarter 2022 financial results conference call and webcast scheduled for May 4, 2022, at 5:00 a.m. PT (8:00 a.m. ET). The Q1 2022 press release will be made available at 4:30 a.m. PT (7:30 a.m. ET) on the same day. Investors can join via a domestic dial-in number (800-895-3361) or international dial-in number (785-424-1062), using the conference ID: NBIX. The webcast link will be accessible on the Neurocrine Biosciences website, with a replay available for one month.
Neurocrine Biosciences announced that valbenazine met its primary endpoint in the Phase 3 KINECT-HD study, showing a significant improvement in chorea severity in Huntington disease patients compared to placebo (p<0.0001). Improvements were evident as early as Week 2. Response rates for clinical and patient global impressions also favored valbenazine. The company plans to submit a supplemental new drug application to the FDA in 2022. The safety profile was consistent with prior studies, with no serious adverse events reported.
Neurocrine Biosciences (Nasdaq: NBIX) announced on March 28, 2022, that its collaboration partner, Mitsubishi Tanabe Pharma Corporation, received regulatory approval from the Japanese Ministry of Health for DYSVAL® (valbenazine) capsules 40 mg, aimed at treating tardive dyskinesia (TD). This approval signifies a key milestone in their partnership established in March 2015, under which MTPC covers all costs related to development and commercialization in Japan and select Asian markets. Neurocrine will earn tiered royalties on future sales, bolstering its financial outlook.
Neurocrine Biosciences (Nasdaq: NBIX) will present new research on treatment patterns and unmet needs for congenital adrenal hyperplasia (CAH) at the AMCP 2022 annual meeting in Chicago from March 29 to April 1. The studies highlight the challenges in managing classic CAH, for which no non-steroidal FDA-approved treatments exist. Current treatment relies on glucocorticoids, posing risks of complications. The company is developing crinecerfont, a non-steroidal CRF1 receptor antagonist, advancing two Phase 3 studies for both adults and children with classic CAH.
FAQ
What is the current stock price of Neurocrine Biosciences (NBIX)?
What is the market cap of Neurocrine Biosciences (NBIX)?
What does Neurocrine Biosciences Inc. specialize in?
What are some key products of Neurocrine Biosciences?
What recent advancements has Neurocrine Biosciences made?
Who announced their retirement from Neurocrine Biosciences in 2024?
What is the focus of Neurocrine Biosciences' muscarinic receptor portfolio?
Where is Neurocrine Biosciences headquartered?
How can I learn more about Neurocrine Biosciences?
What impact has INGREZZA had on Neurocrine Biosciences?
What are the CAHtalyst™ studies?
What was the focus of Neurocrine Biosciences' recent presentations at ENDO 2024?
